MedTrace Logo

Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI

NCT04005729 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-12-03

No results posted yet for this study

Summary

The main objective of the trial is to find out if 4-hour continuous infusion of parenteral P2Y12 inhibitor cangrelor at the start of primary percutaneous coronary intervention (PCI) immediately and effectively suppresses platelet activity in comatose survivors of out-of-hospital cardiac arrest (OHCA). Half of the participants will receive the standard care of dual antiplatelet therapy - acetysalicylic acid and ticagrelor tablets via nasogastric or orogastric tube and the other half the standard care with additional cangrelor infusion at the start of the PCI.

Conditions

  • Out-Of-Hospital Cardiac Arrest
  • Acute Coronary Syndrome

Interventions

DRUG

Cangrelor 50 MG

30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min

Sponsors & Collaborators

  • Chiesi Slovenija, d.o.o.

    collaborator INDUSTRY

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Marko Noc, MD PhD · University Medical Centre Ljubljana

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2021-11-27
Completion
2021-11-27

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04005729 on ClinicalTrials.gov